Search Results - Mabudian, Mohsen I

  • Showing 1 - 6 results of 6
Refine Results
  1. 1
    Efficacy and Tolerability Of Privigen® In Clinical Practice

    Efficacy and Tolerability Of Privigen® In Clinical Practice by Dorsey, Morna J., Dr, Ho, Viet, Mabudian, Mohsen I., Dr, Soler-Palacín, Pere, Domínguez-Pinilla, Nerea, Hellmers, Robert W., Dr, Rishi, Radha Gandhi, Dr, Rishi, Rahul, Wong, Duane W., Dr, Rojavin, Mikhail, Dr, Hubsch, Alphonse, Dr, Berger, Melvin, Dr

    Get full text
    Article
    Save to List
    Saved in:
  2. 2
    Efficacy and Tolerability Of Privigen registered In Clinical Practice

    Efficacy and Tolerability Of Privigen registered In Clinical Practice by Dorsey, Morna J, Ho, Viet, Mabudian, Mohsen I, Soler-Palacin, Pere, Dominguez-Pinilla, Nerea, Hellmers, Robert W, Rishi, Radha Gandhi, Rishi, Rahul, Wong, Duane W, Rojavin, Mikhail, Hubsch, Alphonse, Berger, Melvin

    Get full text
    Article
    Save to List
    Saved in:
  3. 3
    Predicting posttransplant diabetes

    Predicting posttransplant diabetes by Mabudian, Mohsen I., Thomson, Jessica L., Sialkow, J., Arora, Beena, Wiley, Kathleen R., Frey, Daniel, Kumar, Prem

    Published in Human immunology
    Get full text
    Article
    Save to List
    Saved in:
  4. 4
    Long-term safety of facilitated subcutaneous immunoglobulin 10% treatment in patients with primary immunodeficiency diseases: final analysis from a post-authorization safety study conducted in the USA

    Long-term safety of facilitated subcutaneous immunoglobulin 10% treatment in patients with primary immunodeficiency diseases: final analysis from a post-authorization safety study... by Rubinstein, Arye, Mabudian, Mohsen, McNeil, Donald, Patel, Niraj, Wasserman, Richard, Gupta, Sudhir, Carrasco, Paz, Nagy, Andras, Yel, Leman

    Get full text
    Items that cite this one
    Article
    Save to List
    Saved in:
  5. 5
    Long-Term Safety of Facilitated Subcutaneous Immunoglobulin 10% Treatment in US Clinical Practice in Patients with Primary Immunodeficiency Diseases: Results from a Post-Authorization Safety Study

    Long-Term Safety of Facilitated Subcutaneous Immunoglobulin 10% Treatment in US Clinical Practice in Patients with Primary Immunodeficiency Diseases: Results from a Post-Authorizat... by Rubinstein, Arye, Mabudian, Mohsen, McNeil, Donald, Patel, Niraj C., Wasserman, Richard L., Gupta, Sudhir, Carrasco, Paz, Chen, Jie, Garcia, Enrique, Nagy, Andras, Yel, Leman

    Get full text
    Items that this one cites
    Article
    Save to List
    Saved in:
  6. 6
    Clinical Experience With an L-Proline–Stabilized 10 % Intravenous Immunoglobulin (Privigen®): Real-Life Effectiveness and Tolerability

    Clinical Experience With an L-Proline–Stabilized 10 % Intravenous Immunoglobulin (Privigen®): Real-Life Effectiveness and Tolerability by Dorsey, Morna J., Ho, Viet, Mabudian, Mohsen, Soler-Palacín, Pere, Domínguez-Pinilla, Nerea, Rishi, Radha, Rishi, Rahul, Wong, Duane, Rojavin, Mikhail, Hubsch, Alphonse, Berger, Melvin

    Get full text
    Items that this one cites
    Items that cite this one
    Article
    Save to List
    Saved in:

Search Tools: